J Clin Pathol doi:10.1136/jclinpath-2013-201455
  • PostScript
  • Correspondence

HER2-positive breast cancer metastatic to intracranial meningioma: a case report

  1. Stephen B Fox1
  1. 1Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  2. 2Department of Anatomical Pathology, St. Vincent's Hospital, Fitzroy, Victoria, Australia
  3. 3Department of Neurosurgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia
  1. Correspondence to Dr Mikkaela McCormack, Department of Pathology, Peter MacCallum Cancer Centre, St. Andrews Place East Melbourne, Victoria 3002, Australia; mikkaela{at}

The successful introduction of trastuzumab and other novel tyrosine kinase inhibitors (TKI) for treatment of HER2-positive breast carcinoma has resulted in lengthened survival for affected patients. In the context of this increased survival time, it has since emerged that patients who would otherwise have succumbed to the systemic progression of their disease have an increased propensity to develop metastases within the central nervous system (CNS) when compared with their HER2-negative counterparts.1 Recent literature shows that these metastatic deposits respond poorly to TKI therapy, most likely due to their inability to penetrate the blood brain barrier.2

We write to inform you of the first known reported case documenting a HER2-positive breast carcinoma metastasising to an intracranial meningioma, without evidence of additional CNS involvement. This report serves to highlight our increasing understanding of the pathogenesis of brain metastasis, and how this growing knowledge should …

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article